Roche Close to Buying ONCE according to WSJ

In case you missed our posts on Linked-In and Twitter yesterday, the Wall Street Journal is reporting big news in gene therapy and biopharma this wekend: WSJ reports that Roche is close to closing a deal to buy gene therapy company Spark Therapeutics (ONCE) for close to $5 billion. They claim that the deal could be announced Monday if not sooner. This would be a hefty price tag for Spark since it closed Friday with a market cap just under $2 billion and about $500 million in assets minus liabilities. This news should drive up small and mid-cap gene therapy stocks, at least some of which have been running higher this year already. In fact, this news will probably drive up small and mid-cap biopharma stocks in general since it continues the pace of recent multi-billion dollar acquisitions.

At Amp, the gene therapy stocks we follow, some of which are investments, have been running up this year. Check out our Amp Core holdings by becoming an Amp Core subscriber today, and you'll see the ONCE competitor that we like the most.  https://www.ampbioresearch.com/premium-plan

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon